201 related articles for article (PubMed ID: 36008408)
1. Selective suppression of melanoma lacking IFN-γ pathway by JAK inhibition depends on T cells and host TNF signaling.
Shen H; Huang F; Zhang X; Ojo OA; Li Y; Trummell HQ; Anderson JC; Fiveash J; Bredel M; Yang ES; Willey CD; Chong Z; Bonner JA; Shi LZ
Nat Commun; 2022 Aug; 13(1):5013. PubMed ID: 36008408
[TBL] [Abstract][Full Text] [Related]
2. Uncoupling interferon signaling and antigen presentation to overcome immunotherapy resistance due to JAK1 loss in melanoma.
Kalbasi A; Tariveranmoshabad M; Hakimi K; Kremer S; Campbell KM; Funes JM; Vega-Crespo A; Parisi G; Champekar A; Nguyen C; Torrejon D; Shin D; Zaretsky JM; Damoiseaux RD; Speiser DE; Lopez-Casas PP; Quintero M; Ribas A
Sci Transl Med; 2020 Oct; 12(565):. PubMed ID: 33055240
[TBL] [Abstract][Full Text] [Related]
3. Mutations in the IFNγ-JAK-STAT Pathway Causing Resistance to Immune Checkpoint Inhibitors in Melanoma Increase Sensitivity to Oncolytic Virus Treatment.
Nguyen TT; Ramsay L; Ahanfeshar-Adams M; Lajoie M; Schadendorf D; Alain T; Watson IR
Clin Cancer Res; 2021 Jun; 27(12):3432-3442. PubMed ID: 33593882
[TBL] [Abstract][Full Text] [Related]
4. EHBP1L1 Drives Immune Evasion in Renal Cell Carcinoma through Binding and Stabilizing JAK1.
Pan Y; Shu G; Fu L; Huang K; Zhou X; Gui C; Liu H; Jin X; Chen M; Li P; Cen J; Feng Z; Lu J; Chen Z; Li J; Xu Q; Wang Y; Liang H; Wang Z; Deng Q; Chen W; Luo J; Yang J; Zhang J; Wei J
Adv Sci (Weinh); 2023 Apr; 10(11):e2206792. PubMed ID: 36775874
[TBL] [Abstract][Full Text] [Related]
5. Direct AKT activation in tumor-infiltrating lymphocytes markedly increases interferon-γ (IFN-γ) for the regression of tumors resistant to PD-1 checkpoint blockade.
Santinon F; Ezzahra BF; Bachais M; Sarabia Pacis A; Rudd CE
Sci Rep; 2022 Nov; 12(1):18509. PubMed ID: 36323740
[TBL] [Abstract][Full Text] [Related]
6. Immunologic heterogeneity of tumor-infiltrating lymphocyte composition in primary melanoma.
Weiss SA; Han SW; Lui K; Tchack J; Shapiro R; Berman R; Zhong J; Krogsgaard M; Osman I; Darvishian F
Hum Pathol; 2016 Nov; 57():116-125. PubMed ID: 27473267
[TBL] [Abstract][Full Text] [Related]
7. Loss of IFN-γ Pathway Genes in Tumor Cells as a Mechanism of Resistance to Anti-CTLA-4 Therapy.
Gao J; Shi LZ; Zhao H; Chen J; Xiong L; He Q; Chen T; Roszik J; Bernatchez C; Woodman SE; Chen PL; Hwu P; Allison JP; Futreal A; Wargo JA; Sharma P
Cell; 2016 Oct; 167(2):397-404.e9. PubMed ID: 27667683
[TBL] [Abstract][Full Text] [Related]
8. HIF1α-glycolysis engages activation-induced cell death to drive IFN-γ induction in hypoxic T cells.
Shen H; Mullen L; Ojo OA; Xing C; Yassin A; Lewis Z; Bonner JA; Shi LZ
Res Sq; 2024 Jan; ():. PubMed ID: 38260594
[TBL] [Abstract][Full Text] [Related]
9. APLNR Regulates IFN-γ signaling via β-arrestin 1 mediated JAK-STAT1 pathway in melanoma cells.
Liu Y; Ma X; Yang H; Li X; Ma Y; Ason B; Liu S; Hu LA
Biochem J; 2022 Feb; 479(3):385-399. PubMed ID: 35084016
[TBL] [Abstract][Full Text] [Related]
10. Epigenetic reprogramming of tumor cell-intrinsic STING function sculpts antigenicity and T cell recognition of melanoma.
Falahat R; Berglund A; Putney RM; Perez-Villarroel P; Aoyama S; Pilon-Thomas S; Barber GN; Mulé JJ
Proc Natl Acad Sci U S A; 2021 Apr; 118(15):. PubMed ID: 33827917
[TBL] [Abstract][Full Text] [Related]
11. Programmed Death Ligand 1 Indicates Pre-Existing Adaptive Immune Response by Tumor-Infiltrating CD8
Li YM; Yu JM; Liu ZY; Yang HJ; Tang J; Chen ZN
Int J Mol Sci; 2019 Oct; 20(20):. PubMed ID: 31627272
[TBL] [Abstract][Full Text] [Related]
12. Regulation of tumor growth by leukocyte-specific protein 1 in T cells.
Kwon R; Hong BK; Lee KG; Choi E; Sabbagh L; Cho CS; Lee N; Kim WU
J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33020243
[TBL] [Abstract][Full Text] [Related]
13. TNF-α synergises with IFN-γ to induce caspase-8-JAK1/2-STAT1-dependent death of intestinal epithelial cells.
Woznicki JA; Saini N; Flood P; Rajaram S; Lee CM; Stamou P; Skowyra A; Bustamante-Garrido M; Regazzoni K; Crawford N; McDade SS; Longley DB; Aza-Blanc P; Shanahan F; Zulquernain SA; McCarthy J; Melgar S; McRae BL; Nally K
Cell Death Dis; 2021 Sep; 12(10):864. PubMed ID: 34556638
[TBL] [Abstract][Full Text] [Related]
14. Anti-OX40 Antibody Directly Enhances The Function of Tumor-Reactive CD8
Peng W; Williams LJ; Xu C; Melendez B; McKenzie JA; Chen Y; Jackson HL; Voo KS; Mbofung RM; Leahey SE; Wang J; Lizee G; Tawbi HA; Davies MA; Hoos A; Smothers J; Srinivasan R; Paul EM; Yanamandra N; Hwu P
Clin Cancer Res; 2019 Nov; 25(21):6406-6416. PubMed ID: 31371342
[TBL] [Abstract][Full Text] [Related]
15. Progressive upregulation of PD-1 in primary and metastatic melanomas associated with blunted TCR signaling in infiltrating T lymphocytes.
Chapon M; Randriamampita C; Maubec E; Badoual C; Fouquet S; Wang SF; Marinho E; Farhi D; Garcette M; Jacobelli S; Rouquette A; Carlotti A; Girod A; Prévost-Blondel A; Trautmann A; Avril MF; Bercovici N
J Invest Dermatol; 2011 Jun; 131(6):1300-7. PubMed ID: 21346771
[TBL] [Abstract][Full Text] [Related]
16. Targeting Tumor Vasculature with TNF Leads Effector T Cells to the Tumor and Enhances Therapeutic Efficacy of Immune Checkpoint Blockers in Combination with Adoptive Cell Therapy.
Elia AR; Grioni M; Basso V; Curnis F; Freschi M; Corti A; Mondino A; Bellone M
Clin Cancer Res; 2018 May; 24(9):2171-2181. PubMed ID: 29490991
[No Abstract] [Full Text] [Related]
17. Activation of JAK kinases and STAT proteins by interleukin-2 and interferon alpha, but not the T cell antigen receptor, in human T lymphocytes.
Beadling C; Guschin D; Witthuhn BA; Ziemiecki A; Ihle JN; Kerr IM; Cantrell DA
EMBO J; 1994 Dec; 13(23):5605-15. PubMed ID: 7988557
[TBL] [Abstract][Full Text] [Related]
18. [The regulatory function of tumor-infiltrating Th9 cells to anti-tumor activity of CD8(+) T cells in patients with gastric cancer].
Sun PS; Gao ZJ; Fan LX; Liu YF; Chen BH; Mu SZ; Yan ZQ
Zhonghua Zhong Liu Za Zhi; 2022 Nov; 44(11):1186-1193. PubMed ID: 36380667
[No Abstract] [Full Text] [Related]
19. Induction of TRIM22 by IFN-γ Involves JAK and PC-PLC/PKC, but Not MAPKs and pI3K/Akt/mTOR Pathways.
Gao B; Xu W; Wang Y; Zhong L; Xiong S
J Interferon Cytokine Res; 2013 Oct; 33(10):578-87. PubMed ID: 23659673
[TBL] [Abstract][Full Text] [Related]
20. Tumor-targeted interleukin-12 synergizes with entinostat to overcome PD-1/PD-L1 blockade-resistant tumors harboring MHC-I and APM deficiencies.
Minnar CM; Chariou PL; Horn LA; Hicks KC; Palena C; Schlom J; Gameiro SR
J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35764364
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
